These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14592494)

  • 1. Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.
    Hasvold LA; Wang W; Gwaltney SL; Rockway TW; Nelson LT; Mantei RA; Fakhoury SA; Sullivan GM; Li Q; Lin NH; Wang L; Zhang H; Cohen J; Gu WZ; Marsh K; Bauch J; Rosenberg S; Sham HL
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4001-5. PubMed ID: 14592494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.
    Li Q; Claiborne A; Li T; Hasvold L; Stoll VS; Muchmore S; Jakob CG; Gu W; Cohen J; Hutchins C; Frost D; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5367-70. PubMed ID: 15454228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1363-6. PubMed ID: 12657283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.
    Lin NH; Wang L; Cohen J; Gu WZ; Frost D; Zhang H; Rosenberg S; Sham H
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1293-6. PubMed ID: 12657267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor.
    Lin NH; Wang L; Cohen J; Gu WZ; Frost D; Zhang H; Rosenberg S; Sham H
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3821-5. PubMed ID: 14552788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.
    Lin NH; Wang L; Wang X; Wang GT; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5057-62. PubMed ID: 15380198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1359-62. PubMed ID: 12657282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
    Angibaud P; Saha AK; Bourdrez X; End DW; Freyne E; Lezouret P; Mannens G; Mevellec L; Meyer C; Pilatte I; Poncelet V; Roux B; Smets G; Van Dun J; Venet M; Wouters W
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4361-4. PubMed ID: 14643326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents.
    Schlitzer M; Sattler I; Dahse HM
    Bioorg Med Chem; 1999 Sep; 7(9):2037-45. PubMed ID: 10530953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
    J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.
    Li Q; Wang GT; Li T; Gwaltney SL; Woods KW; Claiborne A; Wang X; Gu W; Cohen J; Stoll VS; Hutchins C; Frost D; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5371-6. PubMed ID: 15454229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
    Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
    Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 17. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
    Schlitzer M
    Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
    [No Abstract]   [Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2003; 21():127-44. PubMed ID: 15338743
    [No Abstract]   [Full Text] [Related]  

  • 19. Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.
    Bell IM; Gallicchio SN; Abrams M; Beshore DC; Buser CA; Culberson JC; Davide J; Ellis-Hutchings M; Fernandes C; Gibbs JB; Graham SL; Hartman GD; Heimbrook DC; Homnick CF; Huff JR; Kassahun K; Koblan KS; Kohl NE; Lobell RB; Lynch JJ; Miller PA; Omer CA; Rodrigues AD; Walsh ES; Williams TM
    J Med Chem; 2001 Aug; 44(18):2933-49. PubMed ID: 11520202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.